Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
April 2017
-
Story Discovery
Women in Science: Medy Attalla
-
Story Discovery
The specter of malaria that resists treatment
Great progress has been made against malaria, but signs of resistance are becoming a rising concern
-
Media Release
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet… -
Story Discovery
Loss of friend to liver cancer sharpens focus on experimental therapy
A Novartis experimental drug in clinical trial aims to block liver cancer growth
-
Media Release
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate…
March 2017
-
Story Discovery
Women in Science: Annie Martin
Our Global Head of Precision Medicine in Oncology discusses her day-to-day work at Novartis.
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the… -
Story From Our Labs
Could digital technology drive clinical research in Africa?
Novel digital platform for clinical trial data collection could help facilitate much-needed biomedical research in lower-income countries.
-
Story Discovery
Eyewitness to a healer pursues new treatments for patients
Inspired by her mother, Vicky Qi leads drug discovery teams.
-
Media Release
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
The unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses… -
Story Discovery
Striving to vanquish leukemia
Combination of two compounds shows promise in the lab
-
Media Release
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to…